MEDICAMENT AGAINST DYSMENORRHOEA AND PREMENSTRUAL SYNDROME

Abstract: A local anesthetic is used for the manufacture of a medicament for use against dysmenorrhoea and premenstrual syndrome and for increasing fertility. A pharmaceutical composition may also be used that comprises a pharmaceutically effective dose of a local anesthetic together with a pharmaceutically acceptable excipient. The invention also relates to a process for reducing dysmenorrhoea and premenstrual syndrome symptoms in a woman with said pharmaceutical composition. The pharmaceutical composition may be administered by pertubation.

Description: MEDICAMENT AGAINST DYSMENORRHOEA AND PREMENSTRUAL SYNDROME Prior Application This is a continuation-in-part application of United States Patent Application Serial No. 08/800,737, filed February 15, 1997. Technical Field The present invention relates to the use of a local anesthetic for the manufacture of a medicament for use against dysmenorrhoea and premenstrual syndrome . Background and Summary of the Invention In spite of several previous investigations the causal relationship between reduced fertility and endometriosis without pelvic adhesions is not clear and neither is the lack of an improved fertility rate after treatment. Women with endometriosis also suffer from various degree of dysmenorrhoea but there are no previous reports on increased occurrence of premenstrual syndrome (P S) in endometriotic women. An increased number of leukocytes has been shown in the peritoneal fluid from patients with endometrial peritoneal implants and been considered as an ongoing sterile inflammation. These leukocytes constitute in vivo primed macrophages secreting a macrophage derived growth factor (MDGF) that may explain the proliferation of the endometrial tissue. Peritoneal fluid macrophages in women with endometriosis may also have an increased capacity to resist apoptosis (programmed cell death) and to continue to survive which might be crucial for the fertility. Further phagocytosis of spermatozoa has been found to be increased during incubations for 24 hours in vitro with the peritoneal fluid from patients with endometriosis . Infertility or sub-fertility could be a problem for people afflicted therewith. A common treatment of infertile women is IVF (in vitro fertilization) treatment. The basis of the IVF treatment is as follows: Stimulation of ovulation: Daily hormonal injections, ultrasound examinations and blood samples; Oocyte retrieval: Ultrasound guided ovarian punctures performed vaginally in local anesthesia; Preparation of spermatozoa: Swim-up, swim-down, sperm select or other methods to select the optimal population with the best progressive motility; In vitro fertilization: Incubation of oocytes and the selected population of spermatozoa in a cell incubator. Direct microscopic inspection of cell division and selection of the most vital blastocyte; and Embryo transfer: 2-3 blastocytes with the best vitality is deposited in the uterine cavity for hopeful implantation in the endometrium. IVF treatment is an expensive method that for some couples initiates complicated psychological side effects. The technical and artificial way of trying to become pregnant has the disadvantages for the couple going through the treatment which may adversely affect the relationship. After all the troublesome treatment there is only a pregnancy rate of 25-30%, leaving those who did not succeed with a damaged relationship and still no child. The cost for IVF treatment is around 20,000-25,000 SEK per menstrual cycle . In spite of several previous investigations, the reasons for infertility during endometriosis have not been established and neither has the lack of improved fertility rate after treatment. Particularly the relationship is unclear between mild endometriosis and sub-fertility in the absence of pelvic adhesions. Increased numbers of leukocytes have been found in the peritoneal fluid (PF) from patients with endometrial peritoneal implants and have been considered as an ongoing sterile inflammation. The increased number of leukocytes contained in vivo primed macrophages secreting a macrophage derived growth factor (MDGF) that may explain the proliferation of the endometrial tissue. Other secretory products from the macrophages, growth factors such as TNF and interferon, exhibit gamete toxicity and may also have an adverse impact on the fertility process. Also the cell-free peritoneal fluid is of importance in the reduced fecundity since it has been shown that it significantly reduces the ovum pick up capacity of the fimbriae of the fallopian tubes. In the peritoneal fluid from patients with endometriosis and unexplained infertility, a reduced progressive velocity of spermatozoa has been found. Even more interesting is the increased phagocytosis of spermatozoa that has been found during incubations for 24 hours in vitro with peritoneal fluid from patients with endometriosis. In that particular study there were, however, several different sperm donors and therefore immunological factors involved cannot be excluded. The present invention is an alternative method to the IVF treatment for increasing fertility and for reducing dysmenorrhoea and premenstrual syndrome of women. It has been found by in vitro studies that phagocytosis of spermatozoa is reduced by lidocaine. It is suggested that this effect of lidocaine is due to stabilization of the cell membrane by prohibiting the increase of Na + permeability and by probably interfering with ATP in the cell membrane. The cost for this treatment will be approximately 10% of the IVF treatment, e.g., 2,500 SEK per menstrual cycle. There is no technical fertilization process that can cause psychological side effects. This treatment can be tried in patients with endometriosis and/or slight mechanical cause of infertility. It can be carried out while waiting for IVF and does not affect the possibility of successful later IVF treatment. So far no treatment of infertility with lidocaine is reported in the literature. However, other pharmaceutical effects of lidocaine are known, e.g., as in EP 507 160, which discloses an external preparation for application to the skin containing; lidocaine which comprises a drug-retaining layer placed on a support. The preparation should be used for treatment of herpes zoster neuralgia and postherpetic neuralgia. More particularly, the present invention relates to a local anesthetic that may be used for the manufacture of a medicament for use against dysmenorrhoea and premenstrual syndrome and for increasing fertility. A pharmaceutical composition may also be used that comprises a pharmaceutically effective dose of a local anesthetic together with a pharmaceutically acceptable excipient. The invention also relates to a process for reducing dysmenorrhoea and premenstrual syndrome symptoms in a woman with said pharmaceutical composition. Brief Description of the Drawings As used in the drawings endometr relates to endometriosis and end-prob relates to probable endometriosis . Fig. 1 is a schematic illustration showing the number of free spermatozoa shown for each day of incubation: with cell medium (A, control) , with cell medium and lidocaine (B) , with peritoneal fluid (C, control) and with peritoneal fluid and lidocaine (D) ; Fig. 2 is a schematic illustration showing the number of progressively moving spermatozoa shown for each day of incubation: with cell medium (A, control), with cell medium and lidocaine (B) , with peritoneal fluid (C, control) and with peritoneal fluid and lidocaine (D) ; Fig. 3 is a schematic illustration showing the number of non progressively but moving spermatozoa shown for each day of incubation: with cell medium (A, control), with cell medium and lidocaine (B) , with peritoneal fluid (C, control) and with peritoneal fluid and lidocaine (D) ; Fig. 4 is a schematic illustration showing the number of alive but stationary spermatozoa shown for each day of incubation: with cell medium (A, control), with cell medium and lidocaine (B) , with peritoneal fluid (C, control) and with peritoneal fluid and lidocaine (D) ; and Fig. 5 is a schematic illustration showing the number of dead spermatozoa shown for each day of incubation: with cell medium (A, control) , with cell medium and lidocaine (B) , with peritoneal fluid (C, control) and with peritoneal fluid and lidocaine (D) . Detailed Description With reference to Figs. 1-5, the use of a local anesthetic for the manufacture of a medicament for use against infertility or for increasing fertility. The local anesthetic may be selected from any substance that has a local anesthetic effect. Examples of such substances are bupivacame (1-butyl-N- (2 , 6-dιmethylphenyl) - 2-pιperιdme- carboxamide) , lidocaine (2- (dicthylammo) -N- (2 , 6- dimethylphenyl) acetamide) , mepivacame (N-(2,6- dimethylphenyl) -l-methyl-2-pιperιdιnecarboxamιde) , pnlocaine (N- (2-methylphenyl) -2- (propylarrπno) propanamide) and ropivacame ( (S) -N- (2 , 6-dιmethylphenyl) -l-propy-2- pipendmecarboxamide) . Other local anesthetics could also be used. Preferably lidocaine is used. Another feature of the present invention is a pharmaceutical composition comprising a pharmaceutically effective concentration of a local anesthetic together with a pharmaceutically acceptable excipient. The concentration is one that has an effect on infertility of a woman or one that increases the fertility of a woman. The dose and concentration may be decided by the physician. The concentration of the effective substance is at least 5 μg/ml . One may use 100-2000 μg in 1-20 ml, preferably about 118 μg . The dose that is administrated is at least 100 μg and preferably about 1000 μg . The composition is preferably administered in the peritoneal cavity, preferably by pertubation. The active substance or compound may be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient . The pharmaceutical composition of the present invention may include pharmaceutically acceptable salts of the components herein. Pharmaceutically acceptable salts include the acid addition salts that are formed with inorganic acid such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric and mandelic acid. Physiologically tolerable carriers may also be used. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Further, aqueous carriers may contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol , polyethylene glycol and other solutes . The composition may also comprise hyaluronan which is a viscous substance, e.g., in gel formate. Hyaluronan gives a slow release of the active substance which is preferable as conception may take place up to 24 hours after ovulation and the treatment according to the present invention. Another advantage is that hyaluronan has a stimulating effect on the sperms. Infertility is generally not being considered as an illness. The present invention also embraces a process for treating infertility in a woman with a pharmaceutical composition according to the present invention and may be characterized in that the pharmaceutical composition is inserted by pertubation. The present invention especially relates to a cosmetic or a non-therapeutic method against infertility or for increasing fertility wherein: a) ovulation is diagnosed; and b) a treatment with a local anesthetic is performed when ovulation is expected according to step a) . The treatment is preferably performed by pertubation. Preferably the steps are as follows: Spontaneous ovulation: Primary treatment during normal menstrual cycle. Stimulation only in anovulatory patients and primary with Clomifen (tablets) which is easy and inexpensive. One blood sample is needed post-ovulatory to confirm that there has been an ovulation during the treated cycle. LH (luteinizing hormone) test: The LH-surge 24-36 hours prior to ovulation is diagnosed by self test at home of urine sample. Pertubation: When the LH-test is positive a pertubation treatment is given with, e.g., 10 ml of 100 μg/ml lidocaine in physiological NaCl or Ringer-solution during a normal gynecological examination. There will be no anesthesia needed. Fertilization: Primarily no artificial treatment. The couple will try and achieve pregnancy by normal way by coitus at home after the pertubation treatment is given. If desired, an AIH (Artificial Insemination Husband) may be used. This absence of adverse effects on sperm survival finding demonstrates that the spermatozoa are unaffected by lidocaine which has also been demonstrated in other studies. It seems to be the case also for the oocytes since high levels of lidocaine have been measured without any problems with fertilization or embryo development. The highest levels were 118 μg/ml which means that the dose of 1000 μg of lidocaine given in the in vitro incubations ought to be able to be used diluted to, e.g., 100 μg/ml in 10 ml of isotone fluid. This concentration has been used for a clinical study of pregnancy outcome after pertubation carried out 24 hours preovulatory to increase sperm survival . Permission has been received from the Swedish FDA for increasing the does to about 2 mg/ml . Lidocaine has been used for many years without any reports of adverse effects during pregnancy as has also been shown in an animal study and should therefore be possible to use for treatment of infertility in the endometriotic patient . The invention may be illustrated by the following example. All technical and scientific terms used are, unless otherwise defined, intended to have the same meaning as commonly understood by one of ordinary skill in the art. Example 1 - Reduction of phagocytosis of spermatozoa in PF (peritoneal fluid) from women with endometriosis. This study was undertaken to further analyze the function of the leukocytes in the reduced fertility during endometriosis and also search for a potential therapeutic approach. To exclude immunological influences only one sperm donor was participating in the experiments. Prepared sperm samples was incubated with non-centrifuged peritoneal fluid from healthy women and women with endometriosis to evaluate the importance of phagocytosis of spermatozoa on the reduced fecundity during endometriosis. The number of viable spermatozoa in the incubations were counted daily for five days with or without the presence of local anesthetics that was added in search of a method to reduce the activity of the peritoneal leukocyte populations. The patients were divided into three different groups. The control material (n=9, mean age = 38.5 years) consisted of women going through laparoscopic sterilization or women with unclear abdominal pain. The control cases had laparoscopic findings considered as normal with anatomically normal uterus and fallopian tubes. The study group were women going through laparoscopy to find the cause of infertility or of abdominal pain and where the diagnosis was endometriosis (n=ll, mean age = 34.5 years) . In this group the diagnose was laparoscopic in 8 patients and anamnestic probable endometriosis in 3 patients but who had not yet developed any endometriotic implants that could be seen at the laparoscopy. The sperm donor was a healthy 38 year old male with normal fertility with an continence period of 2-3 days before each sperm sample. The sperm samples were prepared by the swim up technique to select the optimal population. After the patients had been anaesthetized, blood samples were taken for later analyses of hyaluronan, which in PF can be used as a marker of ongoing inflammation to exclude a PID (pelvic inflammatory disease) . At the beginning of the laparoscopy with the instruments safely in the abdominal cavity, all obtainable peritoneal fluid in the Douglas' pouch was aspirated by a suction unit through a Teflon catheter (diameter 1.7 mm, Optinova, Godby, Finland) and mixed with 10 IU of Heparin/ml in a Teflon bottle and immediately taken care of . The amount of peritoneal fluid were determined by weighing on an electric balance. Teflon was the material of choice for collecting the PF due to its low adhesion of mammalian cells. Heparin was used as anticoagulant to prevent the leukocytes from aggregating. Previously citrate has been used which in the sperm incubation had adverse effects on sperm viability. All samples were taken after permissions from the patients and the sampling procedure was approved by the Ethical Committee, Faculty of Medicine, Uppsala University, Sweden. Teflon vials were used for all incubations that were done in a humid cell incubator as follows: a) Cell medium (1 ml) , spermatozoa (10 6 in 1 ml cell medium) and 0 , 1 ml NaCl; b) Cell medium (1 ml) , spermatozoa (10 6 in 1 ml cell medium) and 0 , 1 ml lidocaine 10 mg/ml (Xylocain, ASTRA) ; c) Spermatozoa (10 6 in 1 ml cell medium) , peritoneal fluid (1 ml) and 0 , 1 ml NaCl; and d) Spermatozoa (10° in 1 ml cell medium) , 0,1 ml lidocaine (10 mg/ml) and peritoneal fluid (1 ml) . Earls cell medium (Sigma) with 0.35% BSA (bovine serum albumin) . The remaining amount of peritoneal fluid was centrifuged and the supernatant frozen (-20° C) for subsequent analyses of hyaluronan. The vials were analyzed daily during five days and the following was counted in all the A-D incubations up to 100 spermatozoa: Number of free spermatozoa non-adherent to leukocytes; Number of spermatozoa with progressive motility ; - Number of spermatozoa with non-progressive movement ; Number of spermatozoa that are stationary and alive; and Number of dead spermatozoa. Also the percentage of viable peritoneal leukocytes were noted daily with the use of Trypan blue. The main finding was that there were statistically significantly less phagocytized spermatozoa (p < 0.02) in the vials when incubated with peritoneal fluid and lidocaine. The spermatozoa were observed caught in large aggregates of leukocytes and some apparently undergoing phagocytosis thus reducing the number of free functioning spermatozoa . After two days of incubation there where statistically significantly more free spermatozoa in the incubations with peritoneal fluid from the normal group compared to the group with endometriosis (Kruskal Wallis p<0.014) . No adverse effects were found on sperm survival and there were statistically no significantly differences between the incubations of spermatozoa with or without lidocaine after 24 or 48 hours. The p-values using Wilcoxon are shown in Tables I and II, respectively. The progressive motility is reduced more rapidly without the presence of peritoneal fluid (see Fig. 2) compared to the incubation of spermatozoa alone. In the presence of peritoneal fluid and lidocaine there were significantly more free spermatozoa, especially after two days incubations in the endometriosis group (see Fig. 1 and Table II) . There were more dead spermatozoa in incubations with lidocaine over time in both diagnosis groups (see Fig. 5 and Table II) . Hyaluronan concentrations in peritoneal fluid exhibited no indications of ongoing inflammatory process, i.e., confirming all patients being healthy. TABLE 1: P- values for the different parameters registered in the incubations when comparing with or without incubation with lidocaine. Data after 24 hours incubation time. a) more progressively moving spermatozoa in the incubations without lidocaine. b) more dead in the lidocaine group TABLE II. P-values for the different parameters registered in the incubations when comparing with or without incubation with lidocaine. Data after 48 hour incubation. c) more in lidocaine d) more free in the lidocaine group This investigation includes the impact of lidocaine on sperm survival and effect on the peritoneal leukocyte phagocytosis of spermatozoa in vitro during incubation for five days. This study has included only one donor of spermatozoa to avoid different immunological combinations which would have been uncontrolled factor in the experiments. Also this study follows the sperm survival for up to 5 days whereas previous studies have investigated the sperm survival during a 24 hour period. Further, not only the number of free non-phagocytized spermatozoa was counted but also how many exhibited progressive or stationary movement as well as the number of alive, dead or free (i.e., not adhered to leukocytes) spermatozoa. It was confirmed that the reduced fertility in endometriosis patients was due to sperm phagocytosis. Increased phagocytosis capacity of peritoneal macrophages from patients with endometriosis has also been demonstrated with fluorescent beads. Other studies of sperm phagocytosis have not considered the problem with loss of leukocytes that adhere to some material more than other. Glass containers have been used for storage of peritoneal fluid. Glass has the highest adhesions of leukocytes and has been used for separating macrophages. Polypropylene was chosen which is a better alternative than glass concerning the cell adhesions problem but less optimal than Teflon that was used in the method of the present invention. The finding of more dead spermatozoa in incubations with lidocaine over time must be considered as an effect of the reduced sperm phagocytosis in the presence of lidocaine, since there were, in incubations of spermatozoa alone with or without lidocaine, no adverse effects found on the spermatozoa. This must also be the explanation for the finding of increased non-progressively moving spermatozoa in the lidocaine incubations (see Fig. 3). The reduction of progressive motility without the presence of peritoneal fluid might be an indication of that the PF (peritoneal fluid) contains substances necessary for the spermatozoa to maintain their function. As mentioned in the introduction, the fimbriae of the fallopian tubes are constantly moistured by peritoneal fluid which in the case of patients with endometriosis reduces the capacity of ovum pick up. As demonstrated in this study, the leukocytes in the peritoneal fluid of patients with endometriosis are more potent in phagocytizing spermatozoa. Thus, women with endometriosis can have two factors contributing to their reduced fertility. This study has also indicated the possibility of using the effect of lidocaine in order to reduce the phagocytosis of spermatozoa . In summary, this study has demonstrated a reduced phagocytosis of spermatozoa in the presence of lidocaine. This phenomenon has to be followed up with randomized clinical trials of pertubations with saline or lidocaine/saline solutions preovulatory (LH-surge time) . A study has been undertaken to analyze further the spermatozoa-leucocyte interaction in patients with endometriosis and to find a potential therapeutic approach. To exclude immunological influences only one sperm donor was used. Phagocytosis and sperm viability were assessed during incubations in peritoneal fluid from healthy women and women with endometriosis. The incubations were carried out with or without the supplementation of lignocaine which was chosen due to its previously documented cell membrane stabilizing effect. Thus, the hypothesis was that lignocaine could block the phagocytosis of spermatozoa and incubations were therefore made of the spermatozoa with non- centrifuged peritoneal fluid, i.e., containing phagocytes. Lignocaine was added to assess the effect on the spermatozoa alone in the cell medium as well as the effect on the phagocytes in the peritoneal fluid. Samples from the incubations were studied daily and the number of viable and dead spermatozoa were counted. The number of free spermatozoa, not adhered to leucocytes, was significantly increased when incubated in human peritoneal fluid supplemented with lignocaine. Thus, lignocaine contributes to increasing the number of free spermatozoa and maintaining the possibility of fertilizing an oocyte . The administration of the active substances and compounds may be performed in a variety of ways. The active compounds may include, but are not limited to, local anesthetics, physiological saline, Ringer solution, air and fat emulsions. For example, a small thin catheter may be inserted in the cervix or the uterine cavity and a small rubber cuff is filled with saline to prevent retrograde leakage. The fluid may then be infused through the uterine cavity, 10-20 ml is used which means that the fluid has to flood through the tubes since the uterine cavity contains only 1-2 ml. There should be no pressure used or needed since the passage has to be open through the tubes. The fluid has normal room temperature, but can also be of body temperature . The procedure with pertubation has empirically turned out to reduce menstrual pain (dysmenorrhoea) and PMS (premenstrual syndrome) . This may be due to a local effect of local anesthetics (i.e., lignocaine) reducing the endometrial implants or depressing the hormonal activity in the ovaries. Additionally, the reduced dysmenorrhoea and PMS may be due to a mechanical effect of removing mucous plugs or intra-fallopian minor adhesions around endometrial implants. Another factor may be the mechanical effect of the hormonal change due to the improved mechanical flow through the fallopian tubes that could increase the hormonal drainage of peritoneal fluid from the cavity to the uterine cavity. The pertubation procedure also dilutes and reduces the hormonal concentration the in the peritoneal fluid and PMS are thought to partly due the hormonal in serum which is related to the level in the peritoneal cavity. This unexpected reduction of menstrual pain and the PMS from the patients who have been treated with pertubation is new and not described earlier. For patients with endometriosis, treatment with lignocaine might be a means of increasing the chances of conception. A clinical study is ongoing since February 1998 to evaluate this effect in vivo and if the method can be used as an alternative to assisted fertilization such as IVF (in vitro fertilization) . Lignocaine has been used for many years without any reports of adverse effects during pregnancy. During this clinical trial for the treatment of infertility in the endometriotic patient, pertubations has been carried out preovulatory with Ringer solution with or without lignocaine supplementation. Pregnancies has been noted in the group of women participating in the study, pertubation itself, such as is carried out during X-ray examination of the fallopian tubes, may provide a pregnancy rate of 7% and the spontaneous pregnancy rate for women with endometriosis is 5-10%. An interesting side effect that has been noted in the group of women treated is reduction of menstrual pain (dysmenorrhoea) and premenstrual symptom (PMS) . These side effects may have the following potential explanations: Mechanical effect of the pertubations procedure, i.e., cleaning the fallopian tubes and increasing the hormonal uptake from the peritoneal fluid into the uterus and reducing the serum levels and thereby PMS symptoms; Local beneficial effect of local anesthetics and reduction of inflammatory and/or hormonal activity and thereby reducing the pain and the PMS; - The patients get extra attention and it is thus a positive psychological side effect; It is an effect of a component in the catheterused for pertubations, e.g., rest of surfactant after the production and cleaning of the catheter; and It is a combination of two or more of the effects mentioned above. While the present invention has been described in accordance with preferred compositions and embodiments, it is to be understood that certain substitutions and alterations may be made thereto without departing from the spirit and scope of the following claims.

Claims: I claim : 1. A method of reducing dysmenorrhoea in the woman, comprising: administering a compound which acts as a local anesthetic to the woman in an amount sufficient for reducing the woman's dysmenorrhoea. 2. The method according to claim 1, wherein the method further comprises administering the local anesthetic in an amount sufficient for depressing hormonal activity in the woman's ovaries. 3. The method according to claim 1, wherein the step of administering comprises pertubation with a catheter into the woman's cervix. 4. The method according to claim 1, wherein the step of administering comprises pertubation with a catheter into the woman's uterine cavity. 5. The method according to claim 1 wherein the compound which acts as a local anesthetic is selected from the group consisting of bupivacaine, lidocaine, mepivacaine, prilocaine and ropivacaine . 6. A method of reducing endometrial implants in a woman to reduce premenstrual syndrome in the woman, comprising : administering a compound which acts as a local anesthetic to the woman in an amount sufficient for reducing endometrial implants to reduce the woman's premenstrual syndrome . 7. The method according to claim 6 wherein the compound which acts as a local anesthetic is selected from the group consisting of bupivacaine, lidocaine, mepivacaine, prilocaine and ropivacaine. 8. A process for reducing endometrial implants in a woman to reduce dysmenorrhoea in the woman relative to the woman's present dysmenorrhoea, comprising: administering a pharmaceutical composition to the woman, the pharmaceutical composition comprising a pharmaceutically effective concentration of a local anesthetic with a pharmaceutically acceptable excipient, the local anesthetic being in an amount sufficient for reducing endometrial implants to reduce the woman's dysmenorrhoea. 9. A method for reducing endometrial implants in a woman to reduce the woman's premenstrual syndrome symptoms relative to the woman's present premenstrual syndrome symptoms, comprising: administering to the woman a pharmaceutical combination composition comprising a local anesthetic, physiological NaCl and a hyaluronan in an amount effective to reduce endometrial implants and depress the woman's hormonal activity in the woman's ovaries to reduce the woman's premenstrual syndrome symptoms, the local anesthetic being selected from the group consisting of bupivacaine, lidocaine, mepivacaine, prilocaine and ropivacaine, wherein the combination composition comprises at least five μg/ml of the local anesthetic. 10. The method according to claim 9 wherein the step of administering comprises administering the pharmaceutical combination composition to the woman before ovulation of the woman. AMENDED CLAIMS [received by the International Bureau on 2 August 2000 (02.08.00); original claims 1-10 replaced by new claims 1-9 (2 pages)] For: MEDICAMENT AGAINST DYSMENORRHOEA AND PREMENSTRUAL SYNDROME International Application No. PCT/US00/037a2 Filed 12 February, 2000 1. A method o£ reducing dysmenorrhoea in a woman having a uterine cavity, comprising: determining a level of luteinizing hormone of the woma ; mixing a compound which acts as a local anesthetic with a physiological salt to form a mixture; placing the mixture in a catheter; and administering the mixture into the uterine cavity or the woman by pertubation with the catheter in an amount sufficient for reducing the woma '63 dysmenorrhoea. 2. The method according to claim i, wherein the method further comprises administering the local aneethetic in an amount sufficient for depressing hormonal activity in the woman' s ovaries . 3. The method according to claim 1, wherein the step of administering comprises pertubation with the catheter into the woman's cervix. 4. The method according to claim l wherein the compound which acts as a local anesthetic ia selected from the group consisting of bupivacaine, lidocaine, mepivacaine, prilocaine and ropivacaine. 5. A method of reducing premenstrual syndrome in a woman , comprising: determining a level of luteinizing hormone of the woman; mixing a compound which acts as a local anesthetic with a physiological salt to form a mixture; placing the mixture in a catheter,- administering the mixture into the uterine cavity of the woman by pertubation with the catheter in an amount sufficient for reducing the woman's premenstrual syndrome. 6. The method according to claim 5 wherein the compound which acts as a local anesthetic is selected from the group consisting of bupivacaine, lidocaine, mepivacaine, prilocaine and ropivacaine. 7. A process for reducing endometrial implants in a woman to reduce dysmenorrhoea in the woman relative to the woman's present dysmenorrhoea, comprising: administering a pharmaceutical composition to the woman, the pharmaceutical composition comprising a pharmaceutically effective concentration of a local anesthetic with a pharmaceutically acceptable excipient, the local anesthetic being in an amount suf icient for reducing endometrial implants to reduce the woman's dysmenorrhoea. 8. A method or reducing endometrial im lants in a woman to reduce the woman's premenstrual syndrome symptoms relative to the woman's present premenstrual syndrome syptoms, comp ising- administering to the woman a pharmaceutical combination composition comprising a local anesthetic, physiological NaCl and a hyaluronan in an amount effective to reduce endometrial implants and depress the woman' s hormonal activity in the woman's ovaries to reduce the woman's premenstrual syndrome symptoms, the local anesthetic being selected from the group consisting of bupivacaine, lidocaine, mepivacaine, prilocaine and ropivacaine, wherein the combination composition comprises at least five μg/ml of the local anesthetic. 9. The method according to claim 8 wherein the step of administering comprises administering the pharmaceutical combination composition to the woman before ovulation of the woma .

Inventors: EDELSTAM GRETA, EDELSTAM, GRETA
Applicants: EDELSTAM GRETA, EDELSTAM INC, EDELSTAM INC., EDELSTAM, GRETA
Application year: 2000
Main classification: A61K31
IPC codes: A61K31, A61P15